Mentions
Extended reach
Total likes
Video views
AI synopsis
The overall discussions reflect high interest in the study's findings, with comments on Tecfidera's efficacy and MRI improvements, exemplified by phrases like '90% effective' and references to pivotal trials. The tone balances acknowledgment of positive results with caution about endpoints and real-world impact, indicating moderate engagement and perceived significance.
Most posts acknowledge the positive results of the study, emphasizing Tecfidera's effectiveness and relevance.
The discussion shows high interest, with references to specific trials, MRI results, and implications for treatment decisions.
Posts actively engage with the data by comparing treatments, suggesting discussions with providers, and referencing related trials, indicating moderate depth.
While the posts highlight the potential significance of the findings for MS treatment, they also caution about endpoints and real-world applications, suggesting moderate impact.
Tecfidera, often considered to be a lower-efficacy disease modifying therapy for MS was still 90% effective at stopping gadolinium enhancing lesions compared to placebo (column 2). A reminder that MRI endpoints do not equal disability endpoints. https://t.co/0kFLxAqQy2 https://t.co/982bUmc2cy
How Good is Tecfidera Long-Term? https://t.co/io7bASi0ot
@djcrva I would suggest you talk with your provider about this question. You can take a look at the DEFINE trial (one of the pivotal trials for tecfidera prior to FDA approval) to see some of the data: https://t.co/ZE9LMmUzYl https://t.co/KGHABR0l9Z
RT @Brandon_Beaber: How Good is Tecfidera Long-Term? https://t.co/io7bASi0ot
RT @Brandon_Beaber: Tecfidera, often considered to be a lower-efficacy disease modifying therapy for MS was still 90% effective at stopping…
RT @Brandon_Beaber: Tecfidera, often considered to be a lower-efficacy disease modifying therapy for MS was still 90% effective at stopping…
This video reviews Tecfidera and shows the results of an observational study over 65 years explaining the effectiveness and side effects. It discusses how oral BG-12 significantly reduces relapse rates and disease…
This video analyzes the results of randomized controlled trials involving multiple sclerosis treatments, focusing on their effectiveness in preventing disability progression. Key findings reveal that ofatumumab…
RT @Brandon_Beaber: How Good is Tecfidera Long-Term? https://t.co/io7bASi0ot
RT @Brandon_Beaber: How Good is Tecfidera Long-Term? https://t.co/io7bASi0ot
RT @Brandon_Beaber: How Good is Tecfidera Long-Term? https://t.co/io7bASi0ot
RT @Brandon_Beaber: How Good is Tecfidera Long-Term? https://t.co/io7bASi0ot
How Good is Tecfidera Long-Term? https://t.co/io7bASi0ot
RT @Brandon_Beaber: Tecfidera, often considered to be a lower-efficacy disease modifying therapy for MS was still 90% effective at stopping…
RT @Brandon_Beaber: Tecfidera, often considered to be a lower-efficacy disease modifying therapy for MS was still 90% effective at stopping…
RT @Brandon_Beaber: Tecfidera, often considered to be a lower-efficacy disease modifying therapy for MS was still 90% effective at stopping…
RT @Brandon_Beaber: Tecfidera, often considered to be a lower-efficacy disease modifying therapy for MS was still 90% effective at stopping…
RT @Brandon_Beaber: Tecfidera, often considered to be a lower-efficacy disease modifying therapy for MS was still 90% effective at stopping…
RT @Brandon_Beaber: Tecfidera, often considered to be a lower-efficacy disease modifying therapy for MS was still 90% effective at stopping…
RT @Brandon_Beaber: Tecfidera, often considered to be a lower-efficacy disease modifying therapy for MS was still 90% effective at stopping…
Tecfidera, often considered to be a lower-efficacy disease modifying therapy for MS was still 90% effective at stopping gadolinium enhancing lesions compared to placebo (column 2). A reminder that MRI endpoints do not equal disability endpoints. https://t.co/0kFLxAqQy2 https://t.co/982bUmc2cy
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis | NEJM https://t.co/Pw2RZYJbJr https://t.co/dwRxvpKAm2
@djcrva I would suggest you talk with your provider about this question. You can take a look at the DEFINE trial (one of the pivotal trials for tecfidera prior to FDA approval) to see some of the data: https://t.co/ZE9LMmUzYl https://t.co/KGHABR0l9Z
DB
S
CG
VP
L
DW
AP
J
KM